STOCK TITAN

Theratechnologies Inc. - THTX STOCK NEWS

Welcome to our dedicated news page for Theratechnologies (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theratechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theratechnologies's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary
Theratechnologies Inc. has entered into an agreement with Marathon Asset Management to amend its credit agreement, lowering the minimum liquidity requirement to $15 million until October 31, 2023. The company is taking steps to ensure compliance with the liquidity covenant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
management
Rhea-AI Summary
Theratechnologies Inc. announces a consolidation of its common shares to regain compliance with NASDAQ listing requirements. The consolidation will be effective on July 31, 2023, with each four pre-consolidation shares being consolidated into one post-consolidation share. No shareholder approval is required. The company expects to have approximately 24,201,835 common shares issued and outstanding after the consolidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.99%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary
Theratechnologies has announced that the FDA has agreed to the amended protocol for the Phase 1 clinical trial of sudocetaxel zendusortide, a peptide-drug conjugate that targets cancer cells. The trial will now focus on patients with ovarian cancer and will include weekly dosing. The FDA has also lifted the partial clinical hold on the trial. Theratechnologies will host a conference call on June 13 to provide insights on the data presented at ASCO 2023 and the amended trial protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.47%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Theratechnologies Inc.

Nasdaq:THTX

THTX Rankings

THTX Stock Data

65.29M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.